{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:50:21Z","timestamp":1794369021462,"version":"4.9.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.modpat.2023.100397","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T12:13:17Z","timestamp":1701432797000},"page":"100397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kikkeri N.","family":"Naresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Nejati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.modpat.2023.100397_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.modpat.2023.100397_bib2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ajh.26915","article-title":"Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations","volume":"98","author":"Mangaonkar","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.modpat.2023.100397_bib3","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/2643-3230.BCD-22-0176","article-title":"The role of inflammation in the initiation and progression of myeloid neoplasms","volume":"4","author":"Balandr\u00e1n","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"8","key":"10.1016\/j.modpat.2023.100397_bib4","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1182\/blood.2021014418","article-title":"Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"139","author":"Weeks","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.modpat.2023.100397_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.modpat.2023.100397_bib6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.pathol.2021.02.005","article-title":"Clonal haematopoiesis of emerging significance","volume":"53","author":"Hammond","year":"2021","journal-title":"Pathology"},{"issue":"12","key":"10.1016\/j.modpat.2023.100397_bib7","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.3324\/haematol.2020.264143","article-title":"Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms","volume":"106","author":"Schino","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.modpat.2023.100397_bib8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2141.2005.05593.x","article-title":"Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia","volume":"130","author":"Dingli","year":"2005","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.modpat.2023.100397_bib9","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.2019000611","article-title":"Genomic landscape of neutrophilic leukemias of ambiguous diagnosis","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.modpat.2023.100397_bib10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ajh.24031","article-title":"ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia","volume":"90","author":"Elliott","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100397_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","article-title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia","volume":"33","author":"Cross","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.modpat.2023.100397_bib12","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3324\/haematol.2017.165340","article-title":"Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome","volume":"102","author":"Wang","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.modpat.2023.100397_bib13","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1002\/ajh.25811","article-title":"WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): a contemporary series from the Mayo Clinic","volume":"95","author":"Morsia","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.modpat.2023.100397_bib14","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/ng.3420","article-title":"Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network","volume":"47","author":"Caye","year":"2015","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.modpat.2023.100397_bib15","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.modpat.2023.100397_bib16","first-page":"3534","article-title":"European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)","volume":"89","author":"Niemeyer","year":"1997","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.modpat.2023.100397_bib17","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood-2014-08-550483","article-title":"How I treat juvenile myelomonocytic leukemia","volume":"125","author":"Locatelli","year":"2015","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.modpat.2023.100397_bib18","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1182\/blood-2017-07-798157","article-title":"Integrated molecular profiling of juvenile myelomonocytic leukemia","volume":"131","author":"Murakami","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.modpat.2023.100397_bib19","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood-2016-07-728766","article-title":"Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes","volume":"128","author":"Greenberg","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.modpat.2023.100397_bib20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2014.161","article-title":"Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes","volume":"29","author":"Della Porta","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.modpat.2023.100397_bib21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.leukres.2012.02.014","article-title":"Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the D\u00fcsseldorf Registry on myelodysplastic syndromes","volume":"36","author":"Germing","year":"2012","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.modpat.2023.100397_bib22","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.modpat.2023.100397_bib23","doi-asserted-by":"crossref","first-page":"14172","DOI":"10.18632\/oncotarget.7290","article-title":"Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents","volume":"7","author":"Takahashi","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.modpat.2023.100397_bib24","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","article-title":"Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes","volume":"4","author":"Montalban-Bravo","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.modpat.2023.100397_bib25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41591-021-01411-9","article-title":"Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis","volume":"27","author":"Saiki","year":"2021","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.modpat.2023.100397_bib26","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.modpat.2023.100397_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.2021013983","article-title":"TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia","volume":"140","author":"Tashakori","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.modpat.2023.100397_bib28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/his.14726","article-title":"Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia","volume":"81","author":"Fitzpatrick","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.modpat.2023.100397_bib29","doi-asserted-by":"crossref","unstructured":"Nahmod KA, Sasaki K, Ok CY, Loghavi S. Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: a tale of caution. Am J Hematol. Published Online May 27, 2023. https:\/\/doi.org\/10.1002\/ajh.26970","DOI":"10.1002\/ajh.26970"},{"issue":"2","key":"10.1016\/j.modpat.2023.100397_bib30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.modpat.2023.100397_bib31","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.modpat.2023.100397_bib32","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.modpat.2023.100397_bib33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.modpat.2023.100397_bib34","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1002\/cncr.33745","article-title":"Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes","volume":"127","author":"Kanagal-Shamanna","year":"2021","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.modpat.2023.100397_bib35","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/bloodadvances.2019001127","article-title":"The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing","volume":"4","author":"Dalton","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.modpat.2023.100397_bib36","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3324\/haematol.2013.098103","article-title":"p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)","volume":"99","author":"Saft","year":"2014","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.modpat.2023.100397_bib37","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"J\u00e4dersten","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.modpat.2023.100397_bib38","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2017.166173","article-title":"Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes","volume":"102","author":"Meggendorfer","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.modpat.2023.100397_bib39","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.modpat.2023.100397_bib40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.modpat.2023.100397_bib41","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1038\/s41375-019-0457-1","article-title":"Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome","volume":"33","author":"Bono","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.modpat.2023.100397_bib42","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/s41375-022-01592-3","article-title":"Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience","volume":"36","author":"Calabretto","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.modpat.2023.100397_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101280","article-title":"Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome","volume":"34","author":"Karantanos","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100397_bib44","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2021.5297","article-title":"Hypoplastic myelodysplastic syndrome and acquired aplastic anemia: immune-mediated bone marrow failure syndromes (Review)","volume":"60","author":"Votavova","year":"2022","journal-title":"Int J Oncol"},{"issue":"12","key":"10.1016\/j.modpat.2023.100397_bib45","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/sj.leu.2400844","article-title":"Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes","volume":"11","author":"Kitagawa","year":"1997","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.modpat.2023.100397_bib46","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.exphem.2009.04.009","article-title":"Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset","volume":"37","author":"Fozza","year":"2009","journal-title":"Exp Hematol"},{"issue":"22","key":"10.1016\/j.modpat.2023.100397_bib47","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.modpat.2023.100397_bib48","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.18632\/oncotarget.23882","article-title":"Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic\/myeloproliferative neoplasms","volume":"9","author":"Montalban-Bravo","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.modpat.2023.100397_bib49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/bjh.13529","article-title":"TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis","volume":"171","author":"Loghavi","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.modpat.2023.100397_bib50","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.2008.18.2246","article-title":"Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes","volume":"27","author":"Della Porta","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.modpat.2023.100397_bib51","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.modpat.2023.100397_bib52","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41375-023-01818-y","article-title":"Juvenile myelomonocytic leukemia; moving forward","volume":"37","author":"Elghetany","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.modpat.2023.100397_bib53","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41467-022-29142-6","article-title":"Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia","volume":"13","author":"Binder","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.modpat.2023.100397_bib54","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.modpat.2023.100397_bib55","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/bloodadvances.2018019224","article-title":"Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories","volume":"2","author":"Loghavi","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.modpat.2023.100397_bib56","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.3324\/haematol.2018.208082","article-title":"Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the V617F mutation","volume":"104","author":"Patnaik","year":"2019","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.modpat.2023.100397_bib57","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1038\/bcj.2017.66","article-title":"Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis","volume":"7","author":"Patnaik","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.modpat.2023.100397_bib58","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.humpath.2018.10.026","article-title":"Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic leukemia from primary myelofibrosis with monocytosis","volume":"85","author":"Hu","year":"2019","journal-title":"Hum Pathol"},{"issue":"10","key":"10.1016\/j.modpat.2023.100397_bib59","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/s41375-019-0447-3","article-title":"Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia","volume":"33","author":"Lucas","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.modpat.2023.100397_bib60","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/cyto.b.22054","article-title":"ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry","volume":"104","author":"Wagner-Ballon","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.modpat.2023.100397_bib61","doi-asserted-by":"crossref","unstructured":"Tarfi S, Badaoui B, Freynet N, et\u00a0al. Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with associated inflammatory state. Haematologica. Published Online August 14, 2019. https:\/\/doi.org\/10.3324\/haematol.2019.219782","DOI":"10.3324\/haematol.2019.219782"},{"issue":"10","key":"10.1016\/j.modpat.2023.100397_bib62","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.modpat.2023.100397_bib63","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.26828","article-title":"Atypical chronic myeloid leukemia and myelodysplastic\/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management","volume":"98","author":"Patnaik","year":"2023","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.modpat.2023.100397_bib64","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1182\/blood-2012-03-415356","article-title":"Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts","volume":"119","author":"Patnaik","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.modpat.2023.100397_bib65","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","article-title":"Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients","volume":"34","author":"Mangaonkar","year":"2020","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.modpat.2023.100397_bib66","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.modpat.2023.100397_bib67","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1002\/ajh.26858","article-title":"Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements","volume":"98","author":"Siddiqui","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100397_bib68","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1309\/AJCP48AJDCKTHUXC","article-title":"Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia","volume":"136","author":"Cui","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"24","key":"10.1016\/j.modpat.2023.100397_bib69","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1182\/blood-2011-07-328880","article-title":"NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights","volume":"118","author":"Gough","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.modpat.2023.100397_bib70","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.modpat.2023.100397_bib71","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/blood-2009-08-240457","article-title":"Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1)","volume":"115","author":"Falini","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.modpat.2023.100397_bib72","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1309\/AJCPULO8SLW0RKJL","article-title":"Is the association of \u201ccup-like\u201d nuclei with mutation of the NPM1 gene in acute myeloid leukemia clinically useful?","volume":"134","author":"Bennett","year":"2010","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.modpat.2023.100397_bib73","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/bjh.17347","article-title":"Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia","volume":"192","author":"Loghavi","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.modpat.2023.100397_bib74","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3324\/haematol.2009.017822","article-title":"Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help","volume":"95","author":"Falini","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.modpat.2023.100397_bib75","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","article-title":"mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume":"3","author":"Montalban-Bravo","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.modpat.2023.100397_bib76","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2019000090","article-title":"Clinicopathologic and genetic characterization of nonacute -mutated myeloid neoplasms","volume":"3","author":"Patel","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.modpat.2023.100397_bib77","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.modpat.2023.100397_bib78","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.2020009652","article-title":"CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children\u2019s Oncology Group","volume":"138","author":"Tarlock","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.modpat.2023.100397_bib79","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/blood.2020009680","article-title":"CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome","volume":"139","author":"Taube","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.modpat.2023.100397_bib80","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/bloodadvances.2021004292","article-title":"Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia","volume":"6","author":"Wakita","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.modpat.2023.100397_bib81","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12032-015-0605-z","article-title":"CEBPA methylation and mutation in myelodysplastic syndrome","volume":"32","author":"Wen","year":"2015","journal-title":"Med Oncol"},{"issue":"9","key":"10.1016\/j.modpat.2023.100397_bib82","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.modpat.2023.100397_bib83","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/ajcp\/aqab172","article-title":"Distinct mutation landscapes between acute myeloid leukemia with myelodysplasia-related changes and de novo acute myeloid leukemia","volume":"157","author":"Gao","year":"2022","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2023.100397_bib84","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/modpathol.2014.160","article-title":"Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations","volume":"28","author":"Ohgami","year":"2015","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.modpat.2023.100397_bib85","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.18632\/oncotarget.3460","article-title":"Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes","volume":"6","author":"Devillier","year":"2015","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.modpat.2023.100397_bib86","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.modpat.2023.100397_bib87","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/leu.2016.126","article-title":"RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features","volume":"30","author":"Gaidzik","year":"2016","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.modpat.2023.100397_bib88","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.modpat.2023.100397_bib89","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/modpathol.2010.194","article-title":"Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification","volume":"24","author":"Liu","year":"2011","journal-title":"Mod Pathol"},{"issue":"18","key":"10.1016\/j.modpat.2023.100397_bib90","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood-2016-11-749903","article-title":"More than 1 abnormality is a dominant characteristic of pure erythroid leukemia","volume":"129","author":"Montalban-Bravo","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.modpat.2023.100397_bib91","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/modpathol.2017.175","article-title":"De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity","volume":"31","author":"Reinig","year":"2018","journal-title":"Mod Pathol"},{"issue":"13","key":"10.1016\/j.modpat.2023.100397_bib92","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.modpat.2023.100397_bib93","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bjh.17742","article-title":"De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases","volume":"195","author":"Begna","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.modpat.2023.100397_bib94","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jmoldx.2019.11.004","article-title":"Molecular discordance between myeloid sarcomas and concurrent bone marrows occurs in actionable genes and is associated with worse overall survival","volume":"22","author":"Werstein","year":"2020","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.modpat.2023.100397_bib95","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.humpath.2020.11.005","article-title":"Genomic analysis in myeloid sarcoma and comparison with paired acute myeloid leukemia","volume":"108","author":"Greenland","year":"2021","journal-title":"Hum Pathol"},{"issue":"14","key":"10.1016\/j.modpat.2023.100397_bib96","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.3390\/cancers14143474","article-title":"Systemic mastocytosis and other entities involving mast cells: a practical review and update","volume":"14","author":"El Hussein","year":"2022","journal-title":"Cancers"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223003022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223003022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:26:31Z","timestamp":1760232391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395223003022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0893395223003022"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100397","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100397"}}